Adverse events linked with the use of chimeric and humanized anti ‐CD20 antibodies in children with idiopathic nephrotic syndrome

ConclusionOverall, toxicity of anti‐CD20 monoclonal antibodies was limited to post‐infusion side‐effects in children with more complex disease. The relatively safe profile of anti‐CD20 antibodies support their use as steroid‐sparing agents in children with INS.

Source: British Journal of Clinical Pharmacology - February 13, 2018 Category: Drugs & Pharmacology Authors: Alice Bonanni, Marta Calatroni, Matteo D ’Alessandro, Sara Signa, Enrica Bertelli, Michela Cioni, Eddi Di Marco, Roberto Biassoni, Gianluca Caridi, Giulia Ingrasciotta, Roberta Bertelli, Armando Di Donato, Maurizio Bruschi, Alberto Canepa, Giorgio Piagg Tags: DRUG SAFETY Source Type: research